Pharmaceutical Executive

Pharmaceutical Executive: October 2026
Volume: 46
Issue: 8

Pharmaceutical Executive: September 2026
Volume: 46
Issue: 7
Pharmaceutical Executive: August 2026
Volume: 46
Issue: 6

Pharmaceutical Executive: June 2026
Volume: 46
Issue: 5

Pharmaceutical Executive: May 2026
Volume: 46
Issue: 4

Pharmaceutical Executive: April 2026
Volume: 46
Issue: 3

Pharmaceutical Executive: March 2026
Volume: 46
Issue: 2

Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1

Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9

Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8

Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7

Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6

Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5

Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4

Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3

Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2

Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1

Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12

Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11

Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10

Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9

Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8

Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6

Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5

Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4

Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3

Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1

Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12

Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11

Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
How Pharma Organizations Can Scale AI Agents and Stay Audit-Ready
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
5
